The safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 13, Issue 2, 1999, Pages 77-82

  Mangel, A W ^a   Northcutt, A R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; SEROTONIN 3 ANTAGONIST; CARBOLINE DERIVATIVE; SEROTONIN ANTAGONIST;

ABDOMINAL PAIN; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INFORMATION PROCESSING; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; REVIEW; SEXUAL DEVELOPMENT;

ABDOMINAL PAIN; CARBOLINES; COLONIC DISEASES, FUNCTIONAL; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SEROTONIN ANTAGONISTS; SEX CHARACTERISTICS;

EID: 0032922539     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterol 1991; 100: 998-1005.
2. Camilleri M, Choi M-G. Review article: Irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 3-15.
3. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterol 1994; 107: 271-93.
4. Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroentecol 1997; 112: 1714-43.
5. Scott CM, Grundy D, Boissonade F, Bountra C. Alosetron inhibits the colorectal distension-evoked depressor response and spinal c-fos expression in the anesthetized rat. Gastroenterol 1997; 112: A822 (Abstract).
6. 3 receptor antagonist. Gastroenterol 1998; 114: A804-5.
7. Lembeck F, Skofitsch G. Visceral pain reflex after pretreatment with, capsaicin and morphine. Naunyn-Schmiedebergs Arch Pharmacol 1982; 321: 115-22.
8. Foster JM, Houghton LA, Whorwell PJ. Alosetton slows colonic transit in patients with irritable bowel syndrome. Gastroenterol 1997; 112: A732 (Abstract).
9. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on colonic senstivity in patients with irritable bowel syndrome (IBS). Aliment Pharmacol Ther 1998; 12: 849-55.
10. Bardhan K, Bodemar G, Geldef H, Schultz E, Snell C, Darekar B. A double-bund placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Gastroenterol 1996; 110: A630 (Abstract).
11. 3 receptor antagonist, is effective in the treatment of female irritable bowel syndrome patients. Gastroenterol 1998; 114: A812 (Abstract).
12. Harding JP, Hamm LR, Ehsanullah RSB, et al. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 1073-6.
13. Mangel AW, Hahn BA, Heath AT, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998; 26: 76-81.
14. Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzacca G, Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992; 5: 75-91.